Aging Clinical and Experimental Research

, Volume 6, Issue 3, pp 201–207 | Cite as

Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders

  • Lucilla Parnetti
  • G. P. Reboldi
  • C. Santucci
  • A. Santucci
  • A. Gaiti
  • M. Brunetti
  • R. Cecchetti
  • U. Senin
Original Article


Both low and high platelet MAO-B (pMAO-B) activity is considered an indicator of increased vulnerability in psychopathology. How the activity of this peripheral enzyme can be linked with the sophisticated functions of the central nervous system (CNS) is not clear; in man, evidence exists that the genetic mechanisms determining the size or capacity of the central serotonin system are common to platelet and brain MAO. In the present study pMAO- B activity was evaluated in demented patients suffering from early- onset Alzheimer’s disease (AD), late- onset Alzheimer’s disease (SDAT), vascular dementia (VD), and controls. In these dementia categories, the relationship between pMAO- B activity and clinical features, and between pMAO- B activity and cerebrospinal fluid (CSF) monoamine metabolites (3-methoxy-4-hydroxyphenyl-glycol, MHPG; 5-hydroxy-in-doleacetic acid, 5-HIAA; homovanillic acid, HVA) was also investigated. pMAO-B activity was significantly higher in SDAT patients, compared to controls and AD. Age, as covariate, failed to show any significant effect, and no association was found between pMAO-B activity and CSF monoamine metabolites. The correlation analysis between pMAO-B and neuropsychological scores showed a highly significant positive relationship with GBS- emotional impairment (N=40, r=0.72, p<0.01 in the SDAT group. This result suggests the importance of platelet MAO- B activity as biological marker also in old- age dementias, namely senile dementia of Alzheimer type, where the increased activity of this enzyme might constitute a marker for vulnerability toward behavioural disturbance, i.e., emotional deterioration. (Aging Clin. Exp. Res. 6: 201–207, 1994)


Aging Alzheimer’s disease biological marker dementia disorders platelet MAO-B activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Oreland L., Hallman J.: Blood platelets as a peripheral marker for the central serotonin system. Nord. Psychiatr. Tidssker. 43: 43–51, 1989.CrossRefGoogle Scholar
  2. 2.
    Shalling D., Asberg M., Edman G., Oreland L.: Markers for vulnerability to psychopathology: temperament traits associated with platelet MAO activity. Acta Psychiatr. Scand. 76: 172–182, 1987.CrossRefGoogle Scholar
  3. 3.
    Klinteberg B., Oreland L., Hallman J., Wirsen A., Levander S.E., Schalling D.: Exploring the connections between platelet monoamine oxidase activity and behavior: relationship with performance in neuropsychological tasks. Neuropsychobiology 23: 188–196, 1991.CrossRefGoogle Scholar
  4. 4.
    Castrogiovanni P., Maremmani I., Bongioanni P., Maraziti D.: Platelet monoamine oxidase activity and behavioural characteristics in humans. Neuropsychobiology 91: 173–176, 1991.Google Scholar
  5. 5.
    Lidberg L., Modin I., Oreland L., Tuck J.R., Gillner A.: Platelet monoamine oxidase activity and psychopathy. Psychiat. Res. 16: 339–343, 1985.CrossRefGoogle Scholar
  6. 6.
    Gottfries C.G., Von Knorring L., Oreland L.: Platelet monoamine oxidase activity in mental disorders: 2. Affective psychoses and suicidal behaviour. Prog. Neuropsychopharmacol. 4: 185–192, 1980.PubMedCrossRefGoogle Scholar
  7. 7.
    Wiberg A., Gottfries C.G., Oreland L.: Low platelet monoamine oxidase activity in human alcoholics. Med. Biol. 55: 181–186, 1977.PubMedGoogle Scholar
  8. 8.
    Von Knorring A.L., Bohman M., Von Knorring L., Oreland L.: Platelet MAO activity as biological markers in subgroups of alcoholism. Acta Psychiatr. Scand. 72: 51–58, 1985.CrossRefGoogle Scholar
  9. 9.
    Shekim W., Bylund D., Frankel F., Alexon L., Jones S., Blue L., Kirby J., Corchoran C.: Platelet MAO activity and personality variations in normals. Psychiat. Res. 27: 81–88, 1989.CrossRefGoogle Scholar
  10. 10.
    Davidson J.R.T., Mc Leod M.N., Turnbull C.D., White H.L., Feuer E.J.: Platelet monoamine oxidase activity and the classification of depression. Arch. Gen. Psychiatry 37: 771–773, 1980.PubMedCrossRefGoogle Scholar
  11. 11.
    Schildkraut J.J., Orsulak P.J., Schatzeberg A.F., Herzog J.M.: Platelet monoamine oxidase activity in subgroups of schizofrenic disorders. Schizophr. Bull. 6: 220–225, 1978.CrossRefGoogle Scholar
  12. 12.
    Murphy D., Weiss R.: Reduced monoamine oxidase activity in blood platelets from bipolar depressed patients. Am. J. Psychiatry 128: 1351–1357, 1972.PubMedGoogle Scholar
  13. 13.
    Mann J.: Altered platelet monoamine oxidase activity in affective disorders. Psychol. Med. 9: 729–736, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    Mathew R.J., Beng T., Kralik P., Taylor D., Claghorn J.L.: MAO, DBH and COMT: The effect of anxiety. J. Clin. Psychiatry 41: 25–28, 1980.PubMedGoogle Scholar
  15. 15.
    Oreland L., Wiberg A., Asberg M.: Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiat. Res. 4: 21–29, 1981.CrossRefGoogle Scholar
  16. 16.
    Von Knorring L., Oreland L., Haggendal J., Magnusson T., Almay B., Johansson F.: Relationship between platelet MAO activity and concentrations of 5-HIAA and HVA in cerebrospinal fluid in chronic pain patients. J. Neural Transm. 66: 37–46, 1986.CrossRefGoogle Scholar
  17. 17.
    Shalling D.: The involvement of serotonergic mechanism in anxiety and impulsivity in humans. Behav. Brain Sci. 9: 343–344, 1986.CrossRefGoogle Scholar
  18. 18.
    Oreland L., Arai Y., Stenstrom A.: Age, neuropsychiatric disease and brain monoamine oxidase. In: Tipton K.F., Dostert P., Strolin Benedetti M. (Eds.), Monoamine oxidase and disease. Academic Press, New York, 1984, pp. 91–300.Google Scholar
  19. 19.
    Adolfsson R., Gottfries C.G., Oreland L., Wiberg A., Winblad B.: Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci. 27: 1029–1034, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Alexopoulos G.S., Lieberman K.W., Young R.C.: Platelet MAO activity in primary degenerative dementia. Am. J. Psychiatry 141: 97–99, 1984.PubMedGoogle Scholar
  21. 21.
    Danielczyk W., Streifler M., Konradi C., Riederer P., Moll G.: Platelet MAO-B activity and the psychopathology of Parkinson’s disease, senile dementia and multi-infarct dementia. Acta Psychiatr. Scand. 78: 730–736, 1988.PubMedCrossRefGoogle Scholar
  22. 22.
    Parnetti L., Mecocci P., Reboldi G.P., Santucci C., Brunetti M., Gaiti A., Cadini D., Senin U.: Platelet MAO-B activity and vitamin B12 in old age dementias. Mol. Chem. Neuropatol. 16: 23–32, 1992.CrossRefGoogle Scholar
  23. 23.
    McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M.: Clinical diagnosis of Alzheimer’s disease. Neurology 34: 939–944, 1984.PubMedCrossRefGoogle Scholar
  24. 24.
    Folstein M.F., Folstein S.E., McHugh P.R.: Mini-Mental State: a practical method of grading the cognitive state of patients for clinicians. J. Psychiatr. Res. 12: 189–198, 1975.PubMedCrossRefGoogle Scholar
  25. 25.
    Gottfries C.G., Bråne G., Gullberg B., Steen G.: A new rating scale for dementia syndromes. Arch. Gerontol. Geriatr. 1: 311–330, 1982.PubMedCrossRefGoogle Scholar
  26. 26.
    Parnetti L., Gottfries C.G., Bråne G., Buccolieri A., Veneziano V., Mecocci P., Petrini A., Longo A., Ragni C., Senin U.: La scala GBS per la valutazione delle demenze: studio della inter-rater reliability della versione italiana. Giorn. Gerontol. XXXVII: 293–304, 1989.Google Scholar
  27. 27.
    Eckert B., Gottfries C.G., Von Knorring L., Wiber A., Winblad B.: Brain and platelet monoamine oxidase in mental disorders. I. Schizophrenics and cycloid psychotics. Progr. Neuropsychopharmacol. 4: 57–68, 1980.Google Scholar
  28. 28.
    Lowry O.H, Rosenbrough N.H., Farr A.L., Randall L.J.: Protein measurement with folin reagent. J. Biol. Chem. 193: 265–267, 1951.PubMedGoogle Scholar
  29. 29.
    Parnetti L., Gottfries J., Karlsson I., Langstrom G., Gottfries C.G., Svennerholm L.: Monoamine and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography and gas chromatography-mass spectrometry. Acta Psychiatr. Scand. 75: 542–548, 1987.PubMedCrossRefGoogle Scholar
  30. 30.
    Sakurai E., Yamasaki S., Niwa H., Jossan S.S., Hallman J., Oreland L.: Relation between serotonin and dopamine uptake rates, transmitter concentrations and monoamine oxidase activities in various regions of the rat brain. Biogenic Amines 7: 1–10, 1990.Google Scholar
  31. 31.
    Game N.H., Murphy D.L.: Monoamine oxidase type A: differences in selectivity towards norepinephrine compared to serotonin. Biochem. Pharmac. 31: 4061–4066, 1982.CrossRefGoogle Scholar
  32. 32.
    Strolin-Benedetti M., Boucher T., Fowler C.J.: The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, tolaxantone and MD 770222. Naunyn-Schmiedebergs Arch. Pharmacol. 323: 315–320, 1983.PubMedCrossRefGoogle Scholar
  33. 33.
    Denney R.M., Denney C.B.: An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B. Pharmacol. Ther. 30: 227–259, 1985.PubMedCrossRefGoogle Scholar
  34. 34.
    Oreland L., Engberg G.: Relation between brain monoamine oxidase (MAO) activity and the firing rate of locus coeruleus neurons. Naunyn-Schmiedebergs Arch. Pharmacol. 333: 235–239, 1986.PubMedCrossRefGoogle Scholar
  35. 35.
    Youdim M.B., Ben-Shachar D., Riederer P.: Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron melanin induced neurodegeneration? Acta Neurol. Scand. 126: 47–54, 1989.CrossRefGoogle Scholar
  36. 36.
    Mann J.J., Chiu E.: Platelet monoamine oxidase activity in Huntington’s chorea. J. Neurol. Neurosurg. Psychiatry 41: 809–812, 1978.PubMedCrossRefGoogle Scholar
  37. 37.
    Konradi C., Riederer P., Youdim M.B.H.: Hydrogen peroxide enhances the activity of monoamine oxidase type-B but not of type A: a pilot study. J. Neural Transm. 22: 61–73, 1986.Google Scholar
  38. 38.
    Regland B., Gottfries C.G., Oreland L., Svennerholm L.: Low B12 levels are related to high activity of platelet MAO in patients with dementia disorders. Acta Psychiatr. Scand. 78: 451–457, 1988.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Internal Publishing Switzerland 1994

Authors and Affiliations

  • Lucilla Parnetti
    • 1
  • G. P. Reboldi
    • 2
  • C. Santucci
    • 3
  • A. Santucci
    • 3
  • A. Gaiti
    • 4
  • M. Brunetti
    • 4
  • R. Cecchetti
    • 1
  • U. Senin
    • 1
  1. 1.Sezione di Gerontologia e Geriatria, Dipartimento di Medicina ClinicaPatologia e FarmacologiaItaly
  2. 2.Istituto di Medicina Interna e Scienze Endocrine e MetabolicheItaly
  3. 3.Cattedra di Statistica MedicaItaly
  4. 4.Istituto di Biochimica e Chimica MedicaUniversity of PerugiaPerugiaItaly

Personalised recommendations